Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05502250
Title Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (HOVON164HL)
Acronym HOVON164HL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stichting Hemato-Oncologie voor Volwassenen Nederland
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | BEL

Facility Status City State Zip Country Details
BE-Bruxelles-STLUC NOT_YET_RECRUITING Brussels Belgium Details
DK-Aarhus N-AUH NOT_YET_RECRUITING Aarhus Denmark Details
DK-Copenhagen-RIGSHOSPITALET NOT_YET_RECRUITING Copenhagen Denmark Details
DK-Odense-OUH NOT_YET_RECRUITING Odense Denmark Details
NL-Amersfoort-MEANDERMC NOT_YET_RECRUITING Amersfoort Netherlands Details
NL-Amsterdam-AMC RECRUITING Amsterdam Netherlands Details
NL-Arnhem-RIJNSTATE NOT_YET_RECRUITING Arnhem Netherlands Details
NL-Den Haag-HAGA NOT_YET_RECRUITING Den Haag Netherlands Details
NL-Eindhoven-MAXIMAMC NOT_YET_RECRUITING Eindhoven Netherlands Details
NL-Goes-ADRZ NOT_YET_RECRUITING Goes Netherlands Details
NL-Groningen-UMCG NOT_YET_RECRUITING Groningen Netherlands Details
NL-Hoofddorp-SPAARNEGASTHUIS NOT_YET_RECRUITING Hoofddorp Netherlands Details
NL-Leeuwarden-MCL NOT_YET_RECRUITING Leeuwarden Netherlands Details
NL-Maastricht-MUMC NOT_YET_RECRUITING Maastricht Netherlands Details
NL-Rotterdam-ERASMUSMC NOT_YET_RECRUITING Rotterdam Netherlands Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field